Drug Trial Radar · NCT06012565
KAND567 Versus Placebo in Subjects Hospitalized With COVID-19
Last checked: Nov 19, 2026Latest source record: Aug 25, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
35
Actual
Start
Oct 11, 2020
Primary completion
Aug 7, 2021
Study completion Aug 7, 2021
Sponsor
- Lead sponsor
- Novakand Pharma ABIndustry
- Sponsor type
- Industry
- First posted
- Aug 25, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is a phase II, randomized, 2-arm parallel-group, double-blind study to explore the efficacy, safety, tolerability and pharmacokinetics of KAND567 versus placebo in COVID-19 subjects in need of oxygen treatment. The target was to include forty (40) subjects with diagnosed COVID-19 for participation in the study. If at screening all criteria for study participation were fulfilled and informed consent signed, the subject was enrolled and randomized into one of the two arms. After randomization, the subjects were to receive KAND567 or placebo treatment for 7 days. After the treatment period the subjects returned to ordinary clinical follow-up, but a study follow-up visit was to be planned for Day 21 and 90.
Conditions
- Covid19
Interventions
KAND567Drug
2 x 125 mg capsules for oral administration. KAND567 (250 mg) was to be given every 12 hours for one week (7 days).
Microcrystalline celluloseDrug
Capsules for oral administration, consisting of microcrystalline cellulose oral solid formulation in capsules. Placebo was to be given every 12 hours for one week (7 days).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability of KAND567, as measured by the occurrence of adverse events (AEs) and serious adverse events (SAEs).Time frame: From the first IMP administration (Day 1) until the last follow-up visit (Day 90).
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
Hvidovre Hospital
Hvidovre, Denmark
Odense University Hospital
Odense, Denmark
Capio St. Görans Hospital
Stockholm, Sweden
Västmanlands Hospital
Västerås, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.